Company Preview Steve Berger, Development Director
1
Who We Are
Aptimmune develops and markets a
portfolio of revolutionary
Inactivated Mucosal Vaccines
for diseases of swine.
2
Focus and Pipeline
1
2
3
4
SPECIES
DISEASES
CORE TECHNOLOGIES
PRODUCT LAUNCHES
U.S. Direct Productivity Losses due to PRRSV
4
2011Total PRRSV
Losses:
$665 million
:Viral Respiratory Pathogens
UnaddressedMarket
78%
2015 Influenza
Vaccine Sales
$13 Million
UnaddressedMarket
56%
2015 PRRSV
Vaccine Sales
$53 Million
U.S. PRRSV U.S. Influenza
$120 million overall PRRSV
vaccine opportunity
$60 million overall Influenza
vaccine opportunity
$120 Million overall PRRSV vaccine opportunity
U.S. Direct Productivity Losses due to PRRSV
5
:
2011Total PRRSV
Losses:
$665 million
Viral Respiratory PathogensUnaddressed
Market78%
2015 Influenza
Vaccine Sales
$13 Million
UnaddressedMarket
56%
2015 PRRSV
Vaccine Sales
$53 Million
U.S. PRRSV U.S. Influenza
$120 million overall PRRSV
vaccine opportunity
$60 million overall Influenza
vaccine opportunity
$120 Million overall PRRSV vaccine opportunity
6
BARRICADESM Formulation Technology
7
The PROBLEM with current vaccines:
… 3 things needed to SOLVE the problem:
… to address this, we created a product that is:
High rate of virus mutation
Autogenous Responsive
IneffectiveDelivery
Mucosal Targeted
Live Virus Risks Inactivated Safe/Stable360 - 480 nm
++
ParticleAntigen
Adjuvant
Vaccine Formulation
Intranasal Delivery to Pig
VaccineProduction: BARRICADE™PRRSVAutogenous
PRRS Virus ZMAC – Porcine Alveolar
Macrophage
PRRSV Production on ZMAC
Nano-Particle PRRSV Antigen Adjuvant
Complex
VirusInactivation
8
Production Animal Vaccines – Call for Consistency
“Consistency is the true foundation of trust. Either keep your promises, or do not make them” – Roy T. Bennett
9
Key Characteristics Traditional Autogenous PRRS Barricade Formulation PRRS
Virus Isolation Inconsistent by strain Much more promiscuous substrate
Virus titer Highly variable and not measured Consistent and measured
Formulation and Route of administration
In combo (often) and unnatural Mono-valent and natural
Antigen uptake and processing By chance By design
Reasonable Evidence of Efficacy ?? Established*
*Autogenous product. Efficacy not established by USDA. Indicates non-regulated study observations only.
Swine VaccineCompetitive Position
Conventional Mucosal
Inactivated competitor
MLV/LIVE competitor
10
Preferential Uptake of Nanoparticle-Antigen Complex
Virus control
Fig. 9. PRRSV antigens entrapped nanoparticles engulfed by alveolar
macrophages (Mfs). Scanning electron micrographs of PLGA [poly (DL-lactide-co-
glycolide)] microspheres (nanoparticles). Confocal micrographs of PRRSV antigens
entrapped nanoparticles: (b) Nanoparticles both on the surface and inside pig alveolar
Mfs; (c) Mfs embedded with nanoparticles; (d) fluorochrome labeled PRRSV-N
protein (green) in the engulfed nanoparticles inside the alveolar Mfs.
(a) (b) (c) (d)
Nanoparticle-PRRSV Ags Killed-PRRSV Ags
PRRSV Uptake by ZMAC
11
Aptimmune’s vaccine delivers antigen to immune cells comparable to live virus without inducing cell death.
[Dwivedi and Renukaradhya (2012, PLoS One); Renukaradhya et al. (2015)]
Adjuvant Immune Stimulation Activity
0
2000
4000
6000
8000
10000
12000
14000
16000
ZMAC TNF-α Stimulation by Adjuvant
LAM (Lipoarabinomannan)
LPS (Lipopolysaccharides)
APA (Aptimmune Proprietary Adjuvant)
LAM LPS APA
12
Aptimmune’s proprietary adjuvant provides robust stimulation of immune cells.
BARRICADE™Formulation Technology:Early POC Study
13
0
20
40
60
80
100
Mock Vaccine Traditional AutogenousPRRSV IM
BARRICADE™ PRRSV POC Formulation
% o
f p
igs
wit
h v
iru
s in
th
eir
lun
gs
@ 2
1d p
ost
ch
all
en
ge
Aptimmune’s BARRICADE™ Formulation Technology provided superior virus clearance from lung versus mock & traditional autogenous PRRSV vaccines.
1.26x103 *
1.85x10 *
1.24x103 * * BAL = replicating virus titer for positive animals
Applicator Specifications
• 2ml adjustable dose vaccinator
syringe
• Nasal applicator
• Soft medical-grade tubing
• Hose armor spring
• 30mm uni-lock draw-off (clear)
• Heat-sealed bag
• Instructions - English
Top Market Influencers: Top 15 States, Top 50 Producers = 4 KAM & 2 PSV Staff
= Producer
= Key Account Manager
= Professional Services Veterinarian
15
BarricadeSM
Difference
Right PRRSV isolate every time
Revolutionary inactivated mucosalvaccine formulation
Reduce Viral Shed and Spread time to stabilization
Better productivity growth feed conversion
16
Our Expertise
Aaron Gilbertie President & CEO
Angela McFarlandCFO (Fractional)
Federico ZuckermannCSO & Founder
Steve Berger Development Director
17
LEADERSHIP TEAM EXPERIENCE
Aaron GilbertiePresident & CEO
Over 15 years of swine health sales and marketing experience
Angela McFarlandCFO (Fractional)
Over 10 years experience as a CFO;
facilitated successful business exit
Federico ZuckermannFounder
Professor of Immunology; 25 years experience in swine research
Steve Berger Development Director
30 years of USDA-CVB regulated biologics development/
manufacturing experience
Financial Projection
18
SERIES A
Development of BARRICADESM PRRSV Autogenous
Technology transfer to manufacturing
Produce first BARRICADESM PRRSV Autogenous serial
SERIES B ($6.0 Million. Closing early 2017)
US launch of BARRICADESM PRRSV Autogenous and BARRICADESM Flu Autogenous
Launch US Key Account Management and Professional Service Veterinarian team
Develop & launch commercially licensed PRRSV and swine flu products
$0
$1
$2
$3
$4
$5
$6
$7
$8
$9
$10
Sep-16 Sep-17 Sep-18 Sep-19 Sep-20
Mil
lio
ns
Cash
Capital Raised
Projected Revenue
Ba
se B
rea
k-e
ven
Po
int
(Ap
r-19
)
2020 Business Value: $127 Million
$25,538,198
Series A
Series B
Funding Partners
Fox Ventures, LLC
Midwest Angel Investors
19
20
Barricade Launched at American Association of Swine Veterinarians –Denver, CO – February 25, 2017!
Thank you